AR076596A1 - Medicamento para la administracion oral que contiene al menos un estrogeno y/o al menos un gestageno y al menos una cepa de bacterias probioticas - Google Patents
Medicamento para la administracion oral que contiene al menos un estrogeno y/o al menos un gestageno y al menos una cepa de bacterias probioticasInfo
- Publication number
- AR076596A1 AR076596A1 ARP100101772A ARP100101772A AR076596A1 AR 076596 A1 AR076596 A1 AR 076596A1 AR P100101772 A ARP100101772 A AR P100101772A AR P100101772 A ARP100101772 A AR P100101772A AR 076596 A1 AR076596 A1 AR 076596A1
- Authority
- AR
- Argentina
- Prior art keywords
- microg
- gestagen
- probiotic bacteria
- strain
- daily dose
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pregnancy & Childbirth (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente se refiere a un medicamento para la administracion oral que contiene al menos un estrogeno y/o un gestágeno así como al menos una cepa de bacterias probioticas, como, por ejemplo, especies de lactobacilos. El medicamento se usa ya sea para la anticoncepcion oral o para la terapia hormonal (HT) , en donde es, en este caso, puede servir al mismo tiempo para la estabilizacion del ambiente vaginal y, con ello, para la prevencion de enfermedades infecciosas, tales como, por ejemplo, micosis vaginales, vaginosis bacterianas y/o inflamaciones de la vejiga (cistitis bacterianas) o la prevencion de síntomas urogenitales, por ejemplo, dispareunia y disuria. La presente se refiere también a composiciones farmacéuticas, a las unidades de dosis que contienen un medicamento descrito previamente, así como otras unidades de dosis que contienen exclusivamente una cepa de bacterias probioticas. Reivindicacion 7: Medicamento de acuerdo con la reivindicacion 1, caracterizado porque como dosis diaria de un gestágeno están contenidos: drospirenona 0,5 - 5 mg, levonorgestrel 30 - 250 microg, norgestimato 180 - 250 microg, acetato de noretisterona 0,5 - 1 mg, acetato de ciproterona 1 - 2 mg, desogestrel 20 - 150 microg, dienogest 1 - 3 mg, gestodeno 60 - 75 microg, tibolona 2,5 mg. Reivindicacion 9: Medicamento de acuerdo con la reivindicacion 1, caracterizado porque como dosis diaria de un estrogeno están contenidos: etinilestradiol 10 - 50 microg, estradiol 1 - 4 mg, valerato de estradiol 1 - 4 mg, mestranol 50 microg. Reivindicacion 11: Medicamento de acuerdo con la reivindicacion 1, caracterizado porque como dosis diaria de cepa de bacterias prebiotica están contenidas 109 a 1011 KBE (Kolonie Bildende Einheiten, 'unidades formadoras de colonias').
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102009022947 | 2009-05-22 | ||
| DE102009023632 | 2009-05-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR076596A1 true AR076596A1 (es) | 2011-06-22 |
Family
ID=42617521
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100101772A AR076596A1 (es) | 2009-05-22 | 2010-05-21 | Medicamento para la administracion oral que contiene al menos un estrogeno y/o al menos un gestageno y al menos una cepa de bacterias probioticas |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20120189599A1 (es) |
| EP (1) | EP2432474A1 (es) |
| JP (1) | JP2012527413A (es) |
| CN (1) | CN102438628A (es) |
| AR (1) | AR076596A1 (es) |
| CA (1) | CA2762640A1 (es) |
| TW (1) | TW201109019A (es) |
| UY (1) | UY32650A (es) |
| WO (1) | WO2010133314A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2992861B1 (fr) | 2012-07-09 | 2014-10-17 | Probionov | Utilisation de thiosulfate pour potentialiser l'effet anti-pathogene des lactobacilles |
| CN104178437B (zh) * | 2013-11-08 | 2016-08-24 | 苏州欧赛微科生物医药科技有限公司 | 一种卷曲乳杆菌及其在妇科疾病中的应用 |
| CN104546870B (zh) * | 2015-01-27 | 2018-01-12 | 唐凡兰 | 一种避孕药 |
| KR101867768B1 (ko) | 2016-08-12 | 2018-06-15 | 한국식품연구원 | 락토바실러스 아시도필루스를 포함하는 갱년기 예방 또는 치료용 조성물 |
| EP3427745A1 (en) | 2017-07-12 | 2019-01-16 | Nederlandse Organisatie voor toegepast- natuurwetenschappelijk onderzoek TNO | New probiotic composition for prevention of bacterial vaginosis |
| JP2021513507A (ja) * | 2018-02-07 | 2021-05-27 | エステトラ ソシエテ プリーヴ ア レスポンサビリテ リミテ | 心臓血管系への影響を低減した避妊薬組成物 |
| KR102107443B1 (ko) * | 2018-08-31 | 2020-05-07 | (주)바이오리듬 | 여성 갱년기 증상 예방 또는 치료용 유산균 프로바이오틱스 제제 |
| KR20220026201A (ko) * | 2020-08-25 | 2022-03-04 | 고려대학교 산학협력단 | 락토바실러스 퍼멘텀을 포함하는 갱년기 예방 또는 치료용 조성물 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4905300A (en) * | 1999-05-25 | 2000-12-12 | Andrew W. Bruce | Oral administration of lactobacillus for the maintenance of health in women |
| KR100400411B1 (ko) * | 2000-09-09 | 2003-10-01 | 주식회사 바이오프로젠 | 질염 치료용 생균제제 |
| WO2003082306A1 (en) * | 2002-03-28 | 2003-10-09 | Gregor Reid | Lactobacillus iners for the enhancement of urogenital health |
| US7759105B2 (en) * | 2003-08-29 | 2010-07-20 | Cobb & Company, Llp | Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions |
| CN101028289A (zh) * | 2006-03-01 | 2007-09-05 | 大连森佰澳科技有限公司 | 调整菌群预防或治疗细菌性阴道病的益生菌制剂及工艺 |
-
2010
- 2010-05-14 US US13/322,131 patent/US20120189599A1/en not_active Abandoned
- 2010-05-14 WO PCT/EP2010/002965 patent/WO2010133314A1/de active Application Filing
- 2010-05-14 CA CA2762640A patent/CA2762640A1/en not_active Abandoned
- 2010-05-14 CN CN2010800219540A patent/CN102438628A/zh active Pending
- 2010-05-14 EP EP10722604A patent/EP2432474A1/de not_active Withdrawn
- 2010-05-14 JP JP2012511177A patent/JP2012527413A/ja not_active Withdrawn
- 2010-05-21 TW TW099116393A patent/TW201109019A/zh unknown
- 2010-05-21 UY UY0001032650A patent/UY32650A/es not_active Application Discontinuation
- 2010-05-21 AR ARP100101772A patent/AR076596A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UY32650A (es) | 2010-12-31 |
| CA2762640A1 (en) | 2010-11-25 |
| JP2012527413A (ja) | 2012-11-08 |
| TW201109019A (en) | 2011-03-16 |
| EP2432474A1 (de) | 2012-03-28 |
| CN102438628A (zh) | 2012-05-02 |
| WO2010133314A1 (de) | 2010-11-25 |
| US20120189599A1 (en) | 2012-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR076596A1 (es) | Medicamento para la administracion oral que contiene al menos un estrogeno y/o al menos un gestageno y al menos una cepa de bacterias probioticas | |
| ES2625950T3 (es) | Composición farmacéutica para la anticoncepción de emergencia | |
| AU2010237120B2 (en) | Method for on-demand contraception | |
| ES2356408T3 (es) | Medicamento que incluye al menos un gestágeno. | |
| ES2693085T1 (es) | Uso de estriol en bajas dosis | |
| GT201200281A (es) | Formas de dosificación sólidas orales con dosis muy bajas para la hrt | |
| TW200529862A (en) | Extended use combination comprising estrogens and progestins | |
| CO6160297A2 (es) | Uso de valerato de estradiol o 17beta-estradiol en combinacion de dienogest en una terapia oral para mantener y/o incrementar la libido femenina | |
| AR065816A1 (es) | Regimen anticonceptivo oral | |
| JP2011507853A5 (es) | ||
| DOP2006000035A (es) | Preparación farmaceútica para la anticoncepción oral | |
| CO6190606A2 (es) | Preparacion farmeceutica que contiene gestogenos con actividad antiadrogenica para el tratamiento de endometrosis | |
| US11478503B2 (en) | Vitamin B12 compound supplementation methods and compositions | |
| BR112015010650A2 (pt) | composição contendo somente levonorgestrel melhorada para contracepção oral otimizada com conteúdo definido de levonorgestrel, regime de dosagem e preparo farmacêutico | |
| Busse et al. | Case Report Pharmacological Management of Severe Neuropathic Pain in a Case of Eosinophilic Meningitis Related to Angiostrongylus cantonensis | |
| MD335Y (en) | Method for preparing the neck of uterus for induction of delivery in pregnants with prolonged pregnancy | |
| Crook | The currently contraceptives oestrogen used component steroidal of | |
| CN101810626A (zh) | 含孕二烯酮避孕药物制剂 | |
| JP2013523861A5 (es) | ||
| UA99956U (uk) | Спосіб комбінованого лікування лейоміоми матки у поєднанні з аденоміозом | |
| TH80557A (th) | ผลิตภัณฑ์ทางเภสัชกรรมสำหรับการคุมกำเนิดทางช่องปาก | |
| UA98018C2 (ru) | Лекарственное средство с модифицированным характером высвобождения действующего вещества | |
| TH98166B (th) | การจัดการการเกิดการตกเลือดอย่างมากในการจัดควบคุมยาคุมกำเนิดชนิดฮอร์โมนแบบมีการขยายเวลา | |
| CO5200771A1 (es) | Una composicion farmaceutica para ser usada como agente anticonceptivo | |
| TH148141A (th) | การใช้เอสตราไดออลวาเลอเรตหรือเอสตราไดออลร่วมกับไดอีโนเจสต์สำหรับการรักษาโดยให้ทางปากในการตกเลือดในมดลูกแบบที่ทำงานผิดปกติ ร่วมกับยาคุมกำเนิดสำหรับให้ทางปาก |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |